COMPUTATIONAL ANALYSIS OF TRANSCRIPTION FACTORS AS CANCER DRUG TARGETS WITH POTENTIAL INHIBITORS FROM THE NPACT DATABASE
DOI:
https://doi.org/10.56588/iabcd.v2i2.97Keywords:
In silico analysis, Transcription Factors, Natural compounds, Molecular dockingAbstract
Transcription factors have proven to be promising targets for the treatment of cancer. Transcription factors are involved in the production of oxygen. External cervical events are initiated by receptors, such as cytotoxic exposures or cytokine receptors that trigger signalling cascades that activate transcription factors. Transcriptional factors are known to be highly active in most human cancer cells, making them suitable for the study and development of anticancer therapies. Three transcription factors were investigated as potential targets in this study. Analysis of string interactions reveals their interaction network. DNA-TF binding was followed by docking with 96 natural compounds to the DNA binding pocket of the transcription factor. Using post-docking processing, compounds were ranked according to their binding energy, hydrogen bond number, and dissociation constant; Withanolide D targeted more than one transcription factor. Therefore, the compound is suitable for in vitro testing using different cancer cell lines.
References
Agarwal, Shweta, and Ranjana Mehrotra. “An Overview of Molecular Simulation.” JSM Chemistry, vol. 4, no. 2, 2016, pp. 1024–28.
Al-Benna, Sammy, et al. “Diagnosis and Management of Primary Breast Sarcoma.” Breast Cancer Research and Treatment, vol. 122, no. 3, 2010, pp. 619–26, doi:10.1007/s10549-010-0915-y.
Alfonse, Marco, et al. “An Ontology-Based System for Cancer Diseases Knowledge Management.” International Journal of Information Engineering and Electronic Business, vol. 6, no. 6, 2014, pp. 55–63, doi:10.5815/ijieeb.2014.06.07.
Armstrong, Terri, and Mark R. Gilbert. “Central Nervous System Toxicity from Cancer Treatment.” Current Oncology Reports, vol. 6, no. 1, 2004, pp. 11–19, doi:10.1007/s11912-996-0004-x.
Aubry, S., and J. F. Chateil. “Pediatric Radiology.” Journal de Radiologie, vol. 87, no. 7–8, 2006, pp. 899–905, doi:10.1016/s0221-0363(06)74106-3.
Cancer, The, and Genome Atlas. “Integrated Genomic Analyses of Ovarian Carcinoma The Cancer Genome Atlas Research Network.” Nature, vol. 474, no. 7353, 2011, pp. 609–15, doi:10.1038/nature10166.Integrated.
Chaudhary, Kamal Kumar, and Nidhi Mishra. “A Review on Molecular Docking: Novel Tool for Drug Discovery.” JSM Chem, vol. 4, no. 3, 2016, p. 1029.
Dai, Haisu, et al. “PUM1 Knockdown Prevents Tumor Progression by Activating the PERK/EIF2/ATF4 Signaling Pathway in Pancreatic Adenocarcinoma Cells.” Cell Death and Disease, vol. 10, no. 8, Springer US, 2019, doi:10.1038/s41419-019-1839-z.
Didiasova, Miroslava, et al. “Targeting Gli Transcription Factors in Cancer.” Molecules, vol. 23, no. 5, 2018, pp. 1–19, doi:10.3390/molecules23051003.
Foulkes, William D., et al. Advances in Brief The Prognostic Implication of the Basal-Like ( Cyclin E High / P27 Low / P53 ؉ / BRCA1 -Related Breast Cancer. no. 5, 2004, pp. 830–35.
Gschwend, Daniel A., et al. “Molecular Docking towards Drug Discovery.” Journal of Molecular Recognition, vol. 9, no. 2, 1996, pp. 175–86, doi:10.1002/(SICI)1099-1352(199603)9:2<175::AID-JMR260>3.0.CO;2-D.
Hanahan, Douglas, and Robert A. Weinberg. “The Hallmarks of Cancer (Wikipedia Summary).” Cell, vol. 100, no. 1, 2000, pp. 57–70.
Harding, Heather P., et al. “An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative Stress.” Molecular Cell, vol. 11, no. 3, 2003, pp. 619–33, doi:10.1016/S1097-2765(03)00105-9.
Hayward, Kristen L., et al. “Organ-on-a-Chip Systems for Modeling Pathological Tissue Morphogenesis Associated with Fibrosis and Cancer.” ACS Biomaterials Science and Engineering, vol. 7, no. 7, 2021, pp. 2900–25, doi:10.1021/acsbiomaterials.0c01089.
Hosoya, Tomonori, et al. “Global Dynamics of Stage-Specific Transcription Factor Binding during Thymocyte Development.” Scientific Reports, vol. 8, no. 1, 2018, pp. 1–10, doi:10.1038/s41598-018-23774-9.
Huen, Michael S. Y., et al. “BRCA1 and Its Toolbox for the Maintenance of Genome Integrity.” Nature Reviews Molecular Cell Biology, vol. 11, no. 2, Nature Publishing Group, 2010, pp. 138–48, doi:10.1038/nrm2831.
Kapetanovic, I. M. “Computer-Aided Drug Discovery and Development (CADDD): In Silico-Chemico-Biological Approach.” Chemico-Biological Interactions, vol. 171, no. 2, 2008, pp. 165–76, doi:10.1016/j.cbi.2006.12.006.
Keute, Marius, et al. “No Modulation of Pupil Size and Event-Related Pupil Response by Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS).” Scientific Reports, vol. 9, no. 1, Springer US, 2019, pp. 1–10, doi:10.1038/s41598-019-47961-4.
Laakso, Mervi, et al. “Cytokeratin 5/14-Positive Breast Cancer: True Basal Phenotype Confined to BRCA1 Tumors.” Modern Pathology, vol. 18, no. 10, 2005, pp. 1321–28, doi:10.1038/modpathol.3800456.
Levine, Michael. . 2003.
Liu, Kang, et al. “The Cancer/Testis Antigen HORMAD1 Mediates Epithelial–Mesenchymal Transition to Promote Tumor Growth and Metastasis by Activating the Wnt/β-Catenin Signaling Pathway in Lung Cancer.” Cell Death Discovery, vol. 8, no. 1, Springer US, 2022, doi:10.1038/s41420-022-00946-1.
Malik, Navdeep, et al. “The Transcription Factor CBFB Suppresses Breast Cancer through Orchestrating Translation and Transcription.” Nature Communications, vol. 10, no. 1, 2019, pp. 1–15, doi:10.1038/s41467-019-10102-6.
Massarotti, Alberto, et al. “The Tubulin Colchicine Domain: A Molecular Modeling Perspective.” ChemMedChem, vol. 7, no. 1, 2012, pp. 33–42, doi:10.1002/cmdc.201100361.
Miki, Yoshio, et al. “A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1.” Science, vol. 266, no. 5182, 1994, pp. 66–71, doi:10.1126/science.7545954.
Monteiro, Alvaro N. A., et al. “Evidence for a Transcriptional Activation Function of BRCA1 C-Terminal Region.” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 24, 1996, pp. 13595–99, doi:10.1073/pnas.93.24.13595.
Pagadala, Nataraj S., et al. “Software for Molecular Docking: A Review.” Biophysical Reviews, vol. 9, no. 2, Biophysical Reviews, 2017, pp. 91–102, doi:10.1007/s12551-016-0247-1.
Patel, Chirag N., et al. “Identification of Potential Inhibitors of Coronavirus Hemagglutinin-Esterase Using Molecular Docking, Molecular Dynamics Simulation and Binding Free Energy Calculation.” Molecular Diversity, vol. 25, no. 1, Springer International Publishing, 2021, pp. 421–33, doi:10.1007/s11030-020-10135-w.
Pimentel, André Silva, et al. “Molecular Modeling: Advancements and Applications.” Journal of Chemistry, vol. 2013, no. 001, 2013, pp. 2–4, doi:10.1155/2013/875478.
Rosales-Hernandez, M. C., et al. “Molecular Modeling Applied to Anti-Cancer Drug Development.” Anti-Cancer Agents in Medicinal Chemistry, vol. 9, no. 2, 2012, pp. 230–38, doi:10.2174/187152009787313819.
Roy, Rohini, et al. “BRCA1, and BRCA2: Different Roles in a Common Pathway of Genome Protection.” Nature Reviews Cancer, vol. 12, no. 1, Nature Publishing Group, 2012, pp. 68–78, doi:10.1038/nrc3181.
Schlageter, Manuel, et al. “Histopathology of Hepatocellular Carcinoma.” World Journal of Gastroenterology, vol. 20, no. 43, 2014, pp. 15955–64, doi:10.3748/wjg.v20.i43.15955.
Schleinkofer, Karin, et al. “Molecular Docking.” Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine, vol. 443, 2006, pp. 1149–53, doi:10.1007/3-540-29623-9_3820.
Soltanian, Sara, and Maryam M. Matin. “Cancer Stem Cells and Cancer Therapy.” Tumor Biology, vol. 32, no. 3, 2011, pp. 425–40, doi:10.1007/s13277-011-0155-8.
Stratton, Michael R., et al. “The Cancer Genome.” Nature, vol. 458, no. 7239, Nature Publishing Group, 2009, pp. 719–24, doi:10.1038/nature07943.
Szklarczyk, Damian, et al. “STRING V11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-Wide Experimental Datasets.” Nucleic Acids Research, vol. 47, no. D1, Oxford University Press, 2019, pp. D607–13, doi:10.1093/nar/gky1131.
Tanabe, Mizuho, et al. “Activating Transcription Factor 4 Increases the Cisplatin Resistance of Human Cancer Cell Lines.” Cancer Research, vol. 63, no. 24, 2003, pp. 8592–95.
Wang, Tao, et al. “Ribosome Assembly Factor URB1 Contributes to Colorectal Cancer Proliferation through Transcriptional Activation of ATF4.” Cancer Science, vol. 112, no. 1, 2021, pp. 101–16, doi:10.1111/cas.14643.
Xie, Hong, et al. “IRE1α RNase-Dependent Lipid Homeostasis Promotes Survival in Myc-Transformed Cancers.” Journal of Clinical Investigation, vol. 128, no. 4, 2018, pp. 1300–16, doi:10.1172/JCI95864.
Yan, Chunhong, and Paul J. Higgins. “Drugging the Undruggable: Transcription Therapy for Cancer.” Biochimica et Biophysica Acta - Reviews on Cancer, vol. 1835, no. 1, Elsevier B.V., 2013, pp. 76–85, doi:10.1016/j.bbcan.2012.11.002.
